Reference (passed peer review btw):

Muhammad Salman Hameed, Hongxuan Cao, Li Guo, Lei Zeng, Yanliang Ren, Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review, European Journal of Medicinal Chemistry Reports, Volume 12, 2024, 100217, ISSN 2772-4174, https://doi.org/10.1016/j.ejmcr.2024.100217

Try this link if the above doesn’t work (not that it’s worth visiting in the first place…): https://www.sciencedirect.com/science/article/pii/S277241742400089X?via=ihub

  • Hardened Shell@infosec.pubEnglish
    0·
    14 days ago

    That image was generated by AI and edited over. They didn’t even bother correcting all of it or erasing the parts that didn’t make sense.

    Ffs, this is blatant.

      • iAvicenna@lemmy.worldEnglish
        0·
        14 days ago

        what peer review? This is likely one of the many reviewless journals that solely exist to publish, for a generous fee, shit that wouldn’t even pass as an undergrad homework. people then can write in their CVs for grant applications or position applications in low tier universities etc The name of the journal is usually chosen to look fancy and very international so it looks good on your CV. Honestly there are so many such journals now, no one person would be able to tell which is which, it’s a complete mess. Humans find a way of fucking up everything for profit.

    • dingus@lemmy.worldEnglish
      0·
      14 days ago

      Actually that part is a legitimate classification and not part of the AI nonsense. Broadly, lung cancers are classified as either “small cell” cancers or “non small cell” cancers based on how the tumor appears microscopically. The “non small cell” cancers can be further subdivided into various types.

      The reason for this distinction between the two is due to the significant difference in clinical management and prognosis. Having “small cell” lung cancer is effectively a death sentence, whereas the other types are a lot more treatable.